ANGPTL3 Gene Editing: Promise and Prudence

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Refractory hypercholesterolaemia, hypertriglyceridemia or mixed dyslipidaemia. Intervention: CTX310 (CRISPR-Cas9 gene editing targeting ANGPTL3). Primary outcome: Safety (dose-limiting toxic effects).

Alberto Juan Lorenzatti

doi:10.15420/ecr.2026.02

March 10, 2026European Cardiology ReviewOpen Access

ANGPTL3 Gene Editing: Promise and Prudence

View Full Paper

Ask AI

Bookmark

Share

Figures

Key Points

To evaluate the mechanistic rationale, therapeutic promise, and clinical considerations of permanent in vivo ANGPTL3 gene editing for cardiovascular risk reduction.
Reviewed human genetic studies characterizing cardioprotective loss-of-function variants in ANGPTL3 and pharmacological inhibition models.
Assessed initial proof-of-concept evidence from a Phase I trial of CTX310, a lipid nanoparticle-encapsulated CRISPR–Cas9 therapy administered via a single intravenous infusion in refractory dyslipidaemia.
In early clinical evaluation with CTX310, reductions in LDL cholesterol and triglycerides approached 50% and 55%, respectively, within 60 days at the highest dose tested.
ANGPTL3 disruption achieved lipid lowering through LDL receptor-independent pathways on top of maximally tolerated therapies, decreasing overall apolipoprotein B-containing particles.
The irreversible nature of genome editing introduces critical challenges, including unknown long-term safety, potential off-target effects, and individual variation that necessitate prolonged patient follow-up.

Structured PICO

I

Intervention

in vivo gene editing of ANGPTL3

Limitations

Irreversibility of genome editing
Uncertain long-term safety
Potential off-target effects
Small cohort size in early safety data
Substantial upfront costs and ethical considerations

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

In vivo gene editing of ANGPTL3 represents a conceptual escalation from reversible pharmacological modulation to permanent genetic alteration for lipid management and cardiovascular prevention.

Abstract

therapies require chronic administration and remain subject to the well-documented limitations of long-term adherence, tolerability and sustained access. Against this background, in vivo gene editing of ANGPTL3 represents a conceptual escalation from reversible pharmacological modulation to permanent genetic alteration. By aiming to reproduce the naturally occurring, cardioprotective loss-of-function state, ANGPTL3 gene editing challenges existing paradigms of lipid management and raises fundamental questions regarding the future of cardiovascular prevention.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alberto Juan Lorenzatti (2026) conducted an editorial in Refractory hypercholesterolaemia, hypertriglyceridemia or mixed dyslipidaemia. CTX310 (CRISPR-Cas9 gene editing targeting ANGPTL3) was evaluated on Safety (dose-limiting toxic effects).

synapsesocial.com/papers/6a025c93edf6f4813859479d https://doi.org/10.15420/ecr.2026.02

View Full Paper

Ask AI

Bookmark

Share

ANGPTL3 Gene Editing: Promise and Prudence

Figures

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

ANGPTL3 Gene Editing: Promise and Prudence

Figures

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading